Chlorhexidine gluconate

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

1976

www.ebi.ac.uk

First approval year: 1976
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Chlorhexidine gluconate
www.ebi.ac.uk

Molecular weight: 897.77
www.ebi.ac.uk

Structure (SMILES): N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
www.ebi.ac.uk

acriflex
Acriflex
aerocide 1
Aerocide 1
bacticlens
Bacticlens
bioscrub
Bioscrub
brian care
Brian care
cepton
Cepton
cetriclens
Cetriclens
cetriclens fte
Cetriclens fte
chg scrub
Chg scrub
chloraprep
Chloraprep
chlorhex glucon
Chlorhex glucon
chlorhexidine gluconate
Chlorhexidine gluconate
chlorhexidine gluconate component of avagard

And 107 more, listed on the interactive page.

1 1 hexamethylenebis 5 p chlorophenyl biguanide di d gluconate
1,1'-HEXAMETHYLENEBIS(5-(P-CHLOROPHENYL)BIGUANIDE) DI-D-GLUCONATE
2 4 11 13 tetraazatetradecanediimidamide n n bis 4 chlorophenyl 3 12 diimino di d gluconate
2,4,11,13-TETRAAZATETRADECANEDIIMIDAMIDE, N,N''-BIS(4-CHLOROPHENYL)-3,12-DIIMINO-, DI-D-GLUCONATE
avagard component chlorhexidine gluconate
AVAGARD COMPONENT CHLORHEXIDINE GLUCONATE
cepton
chlohexidine gluconate
Chlohexidine gluconate
chloraprep
Chloraprep
ChloraPrep
chloraprep component chlorhexidine gluconate
CHLORAPREP COMPONENT CHLORHEXIDINE GLUCONATE
chlorhexidine d digluconate
chlorhexidine d digluconate mi
Chlorhexidine d-digluconate
CHLORHEXIDINE D-DIGLUCONATE [MI]
chlorhexidine digluconate
Chlorhexidine digluconate
chlorhexidine digluconate solution
CHLORHEXIDINE DIGLUCONATE SOLUTION
CHLORHEXIDINE DIGLUCONATE SOLUTION [EP MONOGRAPH]
chlorhexidine digluconate solution ep monograph
chlorhexidine gluconate

And 26 more, listed on the interactive page.

CAS registry numbers

18472-51-0

ChEMBL ID: CHEMBL4297088
www.ebi.ac.uk

InChIKey: YZIYKJHYYHPJIB-UUPCJSQJSA-N
www.ebi.ac.uk

FDA ingredient codes (UNII)

MOR84MUD8E

29089
5360565
9552081

20791
133054

Applicant: MOLNLYCKE HLTH
Approval date: 17 Sept 1976
Application number: NDA017768

Patents: 2
Designations: 0
Earliest recorded loss of exclusivity: 2 Oct 2027
First in class: No
Fast track: No
Breakthrough designation: No
Orphan designation: No
Priority review: No
Orphan exclusivity: No
Accelerated approval: No
Availability: Over the counter

Administration routes

topical

Mechanisms of action

Mechanism
Cell membrane inhibitor
Action type
Inhibitor
Target
Cell membrane

Condition
Infections
Highest recorded phase
3
Condition identifier
EFO:0000544
Subject identifier
D007239
Condition
Periodontitis
Highest recorded phase
4
Condition identifier
EFO:0000649
Subject identifier
D010518
Condition
HIV Infections
Highest recorded phase
2
Condition identifier
EFO:0000764
Subject identifier
D015658
Condition
Abscess
Highest recorded phase
2
Condition identifier
EFO:0003030
Subject identifier
D000038
Condition
Pneumonia
Highest recorded phase
3
Condition identifier
EFO:0003106
Subject identifier
D011014
Condition
Dental Caries
Highest recorded phase
3
Condition identifier
EFO:0003819
Subject identifier
D003731
Condition
Head and Neck Neoplasms
Highest recorded phase
1
Condition identifier
EFO:0006859
Subject identifier
D006258
Condition
Acanthamoeba Keratitis
Highest recorded phase
3
Condition identifier
EFO:0007126
Subject identifier
D015823
Condition
Candidiasis, Vulvovaginal
Highest recorded phase
2
Condition identifier
EFO:0007543
Subject identifier
D002181
Condition
Clostridium Infections
Highest recorded phase
2
Condition identifier
EFO:1000874
Subject identifier
D003015
Condition
Peri-Implantitis
Highest recorded phase
3
Condition identifier
EFO:1001390
Subject identifier
D057873
Condition
Mucositis
Highest recorded phase
2
Condition identifier
EFO:1001898
Subject identifier
D052016
Condition
Stomatitis
Highest recorded phase
2
Condition identifier
EFO:1001904
Subject identifier
D013280
Condition
Sepsis
Highest recorded phase
2
Condition identifier
HP:0100806
Subject identifier
D018805
Condition
Pharyngitis
Highest recorded phase
4
Condition identifier
MONDO:0002258
Subject identifier
D010612
Condition
Gingivitis
Highest recorded phase
4
Condition identifier
MONDO:0002508
Subject identifier
D005891
Condition
Cystic Fibrosis
Highest recorded phase
2
Condition identifier
MONDO:0009061
Subject identifier
D003550
Condition
Cross Infection
Highest recorded phase
2
Condition identifier
MONDO:0043544
Subject identifier
D003428
Condition
Radiodermatitis
Highest recorded phase
2
Condition identifier
MONDO:0043771
Subject identifier
D011855
Condition
Severe Acute Respiratory Syndrome
Highest recorded phase
2
Condition identifier
MONDO:0100096
Subject identifier
D045169

Condition identifier
EFO_0000544
Highest recorded phase
3
Condition identifier
EFO_0000649
Condition identifier
EFO_0000764
Highest recorded phase
2
Condition identifier
EFO_0003030
Condition identifier
EFO_0003106
Highest recorded phase
3
Condition identifier
EFO_0003819
Highest recorded phase
3
Condition identifier
EFO_0003938
Condition identifier
EFO_0005681
Condition identifier
EFO_0006859
Highest recorded phase
1
Condition identifier
EFO_0007543
Highest recorded phase
2
Condition identifier
EFO_0009373
Condition identifier
EFO_1000874
Highest recorded phase
2
Condition identifier
EFO_1001390
Highest recorded phase
3
Condition identifier
EFO_1001849
Condition identifier
EFO_1001865
Condition identifier
EFO_1001898
Condition identifier
EFO_1001898
Highest recorded phase
2
Condition identifier
EFO_1001904
Highest recorded phase
2
Condition identifier
HP_0001945
Highest recorded phase
1
Condition identifier
HP_0011947
Highest recorded phase
2
Condition identifier
HP_0012531
Condition identifier
HP_0100806
Condition identifier
MONDO_0000918
Highest recorded phase
1
Condition identifier
MONDO_0002258
Condition identifier
MONDO_0002258
Highest recorded phase
4

And 18 more, listed on the interactive page.

Warnings

Warning
Withdrawn
Effect
dermatological toxicity
Description
associated with chemical and thermal burns
Year
1984

Warning
Withdrawn
Effect
dermatological toxicity
Description
associated with chemical and thermal burns
Year
1984
Country
United States
Condition
caustic injury
Warning
Withdrawn
Effect
dermatological toxicity
Description
associated with chemical and thermal burns
Year
1984
Country
United States
Condition
thermal burn

Event
abdominal discomfort
Reports
274
Reporting signal score
632.932
Event
abdominal pain upper
Reports
230
Reporting signal score
424.948
Event
administration site rash
Reports
11
Reporting signal score
63.0033
Event
allergy to chemicals
Reports
7
Reporting signal score
24.3611
Event
alopecia
Reports
274
Reporting signal score
629.077
Event
anaphylactic reaction
Reports
101
Reporting signal score
166.962
Event
anti-cyclic citrullinated peptide antibody
Reports
4
Reporting signal score
18.0366
Event
anti-cyclic citrullinated peptide antibody positive
Reports
262
Reporting signal score
1,390.74
Event
application site erythema
Reports
28
Reporting signal score
64.8884
Event
application site hypersensitivity
Reports
5
Reporting signal score
17.5247
Event
application site irritation
Reports
11
Reporting signal score
24.9051
Event
application site necrosis
Reports
4
Reporting signal score
18.6648
Event
application site papules
Reports
5
Reporting signal score
20.314
Event
application site pruritus
Reports
13
Reporting signal score
24.7451
Event
application site rash
Reports
59
Reporting signal score
215.942
Event
application site reaction
Reports
25
Reporting signal score
87.116
Event
application site vesicles
Reports
17
Reporting signal score
50.8184
Event
arthralgia
Reports
556
Reporting signal score
1,120.87
Event
arthropathy
Reports
281
Reporting signal score
854.864
Event
asthenia
Reports
237
Reporting signal score
274.97
Event
asthenopia
Reports
16
Reporting signal score
49.3577
Event
back pain
Reports
183
Reporting signal score
260.049
Event
blister
Reports
559
Reporting signal score
2,208.7
Event
blood lactate dehydrogenase increased
Reports
16
Reporting signal score
17.4568
Event
body temperature increased
Reports
213
Reporting signal score
768.928

And 120 more, listed on the interactive page.

NCT00006075
clinicaltrials.gov
NCT00066950
clinicaltrials.gov
NCT02001311
clinicaltrials.gov
NCT02598778
clinicaltrials.gov
NCT03061916
clinicaltrials.gov
NCT00123123
clinicaltrials.gov
NCT03442023
clinicaltrials.gov
NCT00425451
clinicaltrials.gov
NCT01030666
clinicaltrials.gov
NCT02215473
clinicaltrials.gov
NCT04027179
clinicaltrials.gov
NCT00528008
clinicaltrials.gov
NCT00549393
clinicaltrials.gov
NCT01495117
clinicaltrials.gov
NCT01613365
clinicaltrials.gov
NCT02160574
clinicaltrials.gov
NCT02160587
clinicaltrials.gov
NCT02221232
clinicaltrials.gov
NCT02296645
clinicaltrials.gov
NCT02490631
clinicaltrials.gov
NCT02915289
clinicaltrials.gov
NCT03423147
clinicaltrials.gov
NCT04218110
clinicaltrials.gov
NCT04756804
clinicaltrials.gov
NCT06126614
clinicaltrials.gov

And 18 more, listed on the interactive page.

Dose: 2 mL
Route: Topical
How often: As needed

Allow to dry before donning gloves
Apply to clean, dry hands and nails

Hydrogen bond acceptors: 4
Hydrogen bond donors: 10
Polar surface area: 167.58
Calculated partition coefficient (ALogP): 4.18
Prodrug: No
Chirality: Achiral
Inorganic: No
Rule-of-five violations: 2
Rotatable bonds: 9
Heavy atoms: 60
Molecular formula: C34H54Cl2N10O14
Monoisotopic mass: 896.3198018
Natural product: No

0116-0003
0116-0101
0116-0175
0116-0200
0116-0301
0116-0407
0116-0800
0116-2001
0116-4075
0116-6000
0116-6720
0121-0893
0121-1786
0126-0272
0126-0282
0374-5080
0404-4075
0904-7035
16571-128
53329-301
53462-003
59883-175
60687-714
61037-469
62135-649

And 27 more, listed on the interactive page.

Recorded assays: 7
Active assays: 0

Anti-Infective Agents, Local
Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects.
Dermatologic Agents
Drugs used to treat or prevent skin disorders or for the routine care of skin.
Anti-Infective Agents, Local
id.nlm.nih.gov
Dermatologic Agents
id.nlm.nih.gov

Related records

Trials (192)

"The Efficacy of Acacia Catechu Mouthrinse as Antiplaque and Antigingivitis Agent in Fixed Orthodontic Appliance Patients.
2% Chlorhexidine Gluconate Skin Cloths to Prevent SSI in Spine Surgery Patients
4% Chlorhexidine Gluconate Daily Bathing for Prevention of Hospital-acquired Infections in Intensive Care Settings
A 96-hour Patch Test Study Using Healthy Human Volunteers to Assess the Skin Irritation Potential of 11 Topically Applied Formulations
A Clinical Study Investigating the Effects of a Dentifrice Containing 67% Sodium Bicarbonate When Used Twice Daily for 12 Weeks on Gingivitis Treatment and Plaque Removal
A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis
A Cluster-randomized Cross-over Trial Evaluating the Comparative Effectiveness of Three Skin Antiseptic Interventions
A Double-blind Randomized Placebo Controlled Clinical Trial Evaluating Effect of Chlorhexidine Gluconate 2% Cloth vs Placebo Cloth Baths on the Incidence of Central Line-Associated Blood Stream Infections in Outpatient Hematopoietic Stem Cell Transplant Patients
A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)
A Pilot Study to Evaluate Skin Swabbing With Chlorhexidine to Prevent Skin And Soft Tissue Infections Among People Who Inject Drugs
A Study of Chlorhexidine in the Prevention of HIV-1 Transmission From Mothers to Their Babies
An Efficacy Study of Chlorhexidine Mouthwashes
An Efficacy Study of Stain Control of a 67% Sodium Bicarbonate Containing Toothpaste on Chlorhexidine Tooth Staining
An Evaluation of the Efficacy of HEXI-PREP by Clinell Wipes
Anti-staining Efficacy of Anti-Discoloration System (ADS) Added to Chlorhexidine (CHX)
Antimicrobial Agent for Reducing Bacteria in Aerosols and Oral Cavity
Antimicrobial Efficacy of Biogenic Gold Nano Particle From Pelargonium Graveolens Leaves Extract Mouthwash for Children
Antimicrobial Photodynamic Therapy Applied in Orthodontic. Orthodontic Patients.
Antiviral Efficacy and Acceptability of Mouth Rinses for Inactivation of COVID-19
Aqueous vs Alcohol Chlorhexidine Skin Preparation for Prevention of Cesarean Section Wound Infections

Approved for (3)

Gingivitis
Periodontitis
Pharyngitis

In development for (14)

Abscess Phase 2
Acanthamoeba keratitis Phase 3
Clostridium infectious disease Phase 2
COVID-19 Phase 2
Cystic fibrosis Phase 2
Dental caries Phase 3
Head and neck cancer Phase 1
HIV infectious disease Phase 2
Mucositis Phase 2
Nosocomial infection Phase 2
Pneumonia Phase 3
Radiodermatitis Phase 2
Stomatitis Phase 2
Vulvovaginal candidiasis Phase 2

Chlorhexidine gluconate

Development status

Names and chemistry

Brand names (132)

Other names (51)

Identifiers

PubChem compound IDs (3)

RxNorm IDs (RxCUI) (2)

Regulatory information

United States

Other regulatory facts

Pharmacology

Drug classification

Administration routes

Mechanisms of action

Investigated indications (20)

Open Targets indications (43)

Warnings

Open Targets warnings (2)

Reported adverse events (145)

Trial references (43)

Dosing

Conditions of use (2)

Chemical properties

National Drug Codes

Evidence counts

Pharmacologic actions

Related records

Trials (192)

Approved for (3)

In development for (14)

Other linked conditions (3)